Shanghai Rightongene Biotechnology (688217.SH) issued a forecast of expected losses, predicting a net loss of 11.29 million to 16.94 million yuan in 2024.

Shanghai Rightongene Biotechnology (688217.SH) announced that it is expected to achieve an operating income of 238 million yuan to 245 million yuan in the fiscal year 2024, which is a decrease of 5.12% to 7.83% compared to the same period last year (as disclosed by law). The company expects to incur a net loss attributable to the owners of the parent company of -11.29 million yuan to -16.94 million yuan in the fiscal year 2024, compared to a profit in the same period last year. The expected net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, in the fiscal year 2024 is -14.797 million yuan to -20.44 million yuan.